Myriad Genetics, Inc. (MYGN) on Tuesday reported first-quarter results with revenue rising slightly from last year, while losses widened compared to the prior period.
The company posted revenue of $200.4 million for the three months ended March 31, 2026, up from $195.9 million a year earlier. Net loss widened to $34.1 million from a near break-even loss of $0.1 million in the prior-year quarter. Loss per share was $0.36 for the quarter, while weighted average shares outstanding stood at 93.7 million.
Operating loss came in at $30.7 million, up from $29.0 million last year, as total operating expenses increased to $168.3 million from $163.2 million. The higher expenses were driven in part by research and development costs of $27.1 million and sales and marketing expenses of $73.6 million.
MYGN is currently trading after hours at $4.47, down $0.56 or 11.13 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.